A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

BACKGROUND: Cancer stem cells (CSCs) are purported to be responsible for tumor initiation, treatment resistance, disease recurrence, and metastasis. CXCR1, one of the receptors for CXCL8, was identified on breast cancer (BC) CSCs. Reparixin, an investigational allosteric inhibitor of CXCR1, reduced...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldstein, Lori J., Perez, Raymond P., Yardley, Denise, Han, Linda K., Reuben, James M., Gao, Hui, McCanna, Susan, Butler, Beth, Ruffini, Pier Adelchi, Liu, Yi, Rosato, Roberto R., Chang, Jenny C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954543/
https://www.ncbi.nlm.nih.gov/pubmed/31924241
http://dx.doi.org/10.1186/s13058-019-1243-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954543/
https://www.ncbi.nlm.nih.gov/pubmed/31924241
http://dx.doi.org/10.1186/s13058-019-1243-8

Ejemplares similares